San Diego Biotech Lays Off Half Its Workers After Failed Drug Trial

Gossamer Bio forced to cut 65 jobs after Phase 3 trial of key lung disease drug seralutinib fails to meet goals.

Apr. 13, 2026 at 10:22pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life of a single glass vial filled with a clear liquid, resting on a clean white background and dramatically lit from the side, conveying a sense of loss and uncertainty in the wake of a failed drug trial.A single glass vial, the lone remaining symbol of a biotech company's failed drug trial, stands as a stark reminder of the high-stakes, high-risk nature of the pharmaceutical industry.San Diego Today

The local biotech company Gossamer Bio is laying off 65 employees, nearly half of its total workforce, after its lead drug candidate seralutinib failed a crucial Phase 3 clinical trial. The company, which is focused on developing treatments for rare lung diseases, warned investors that the failed trial puts its future in jeopardy and that it may not have enough resources to continue developing its other drug candidates.

Why it matters

Gossamer Bio's struggles highlight the high-risk, high-cost nature of drug development, especially for smaller biotech firms. The failure of seralutinib, which was seen as the company's most promising asset, raises doubts about Gossamer's ability to bring any of its drugs to market and casts uncertainty over the future of the $93 million company.

The details

Gossamer Bio announced it will lay off 65 employees, or about 50% of its workforce, effective May 15. The cuts will impact the clinical development team as well as several senior vice president positions. The layoffs come after Gossamer's highly anticipated drug seralutinib failed a crucial Phase 3 clinical trial, with results 'well below what we believe could be considered clinically meaningful,' according to analysts. Gossamer warned investors it may not have enough money or resources to continue developing its other drug candidates, RT234 and PH-ILD, which are also in the pipeline. The company plans to meet with the FDA this quarter to determine the path forward for seralutinib, but cautioned that failure to develop the drug would 'significantly harm' its business.

  • Gossamer Bio announced the Phase 3 failure of seralutinib in March 2026.
  • The 65-employee layoff will take effect on May 15, 2026.

The players

Gossamer Bio

A San Diego-based biotech company focused on developing treatments for rare lung diseases.

Seralutinib

Gossamer Bio's lead drug candidate that failed a crucial Phase 3 clinical trial.

RT234

Another drug candidate in Gossamer Bio's pipeline that is in Phase 2 trials.

PH-ILD

A third drug candidate from Gossamer Bio that entered Phase 3 trials but had enrollment paused as of February 2026.

Chiesi Farmaceutici

An Italian pharmaceutical company that had a collaboration agreement with Gossamer Bio for the development and commercialization of seralutinib.

Got photos? Submit your photos here. ›

What’s next

Gossamer Bio plans to meet with the FDA sometime this quarter to review the results of the seralutinib study and determine the path forward for the drug.

The takeaway

Gossamer Bio's struggles underscore the high-risk, high-cost nature of drug development, especially for smaller biotech firms. The failure of its lead drug candidate seralutinib puts the company's future in jeopardy and raises doubts about its ability to bring any of its other pipeline drugs to market.